Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05477056 · ClinicalTrials.gov registry record
Quality Improvement PrecivityAD Clinician Survey (QUIP I)
A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by C2N Diagnostics.
- Completed
- Registry status
- 366
- Enrollment target
- 1
- Study location
NCT05477056: Completed study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by C2N Diagnostics.
NCT05477056 is a study of Alzheimer Disease and Mild Cognitive Impairment that has completed, run by C2N Diagnostics. The registered enrollment target is 366 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05477056, a study of Alzheimer Disease and Mild Cognitive Impairment, has completed, sponsored by C2N Diagnostics.
- COMPLETED
- Registry status
- 366 participants
- Enrollment target
- 1
- Study location
Study Summary
There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia. MCI impacts 12-18% of people in the United States over age 60 and is often an initial clinical sign of Alzheimer's disease (AD) (Alzheimer's Association, 2022). The PrecivityAD test is an analytically and clinically validated blood test that aids healthcare providers in the diagnosis of AD in patients with MCI and early-stage dementia. C2N has created a quality improvement (QI) survey to gather insight from clinicians as to the clinical effectiveness of the commercially available PrecivityAD™ test, which identifies whether a patient with signs and symptoms of cognitive decline is likely to have amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease.
Primary Outcome
retrospective analysis of clinician survey data collected during a single timepoint
Conditions Studied
Interventions
- OTHER PrecivityAD blood test
Study Locations (1)
Missouri
- C2N Diagnostics - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2022-10-06 |
What the finished NCT05477056 record still lists
NCT05477056 is an observational study that tracks outcomes without assigning an intervention. The registered 366 participants enrollment target is mid-sized for trials with a published cap, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (87% lower).
The record links to 4 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which PrecivityAD blood test is the first listed.
NCT05477056 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05477056 about?
NCT05477056 is a clinical study titled "Quality Improvement PrecivityAD Clinician Survey (QUIP I)". There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia. MCI impacts 12-18% of people in the United States over age 60 and is often an initial clinical sign of Alzheimer's disease (AD) (Alzhei...
What is the current status of trial NCT05477056?
This trial is currently completed. The enrollment target is 366 participants. The study started on 2021-03-01. Estimated completion is 2022-10-06.
What conditions does trial NCT05477056 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline.
What interventions are being tested in trial NCT05477056?
The interventions under investigation include: PrecivityAD blood test (OTHER).
Who is sponsoring clinical trial NCT05477056?
This trial is sponsored by C2N Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05477056 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05477056's enrollment target sits among peer trials
366 68th of 306 higher than 239 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05083481 · 366 participants · Phase 1
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- NCT05429632 · 366 participants · Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- NCT06979453 · 366 participants · Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI